Fundraising Fox
Remedium
Boston, US · Founded 2020 · 20 employees on LinkedIn · 5 known investors
Find your way into Remedium
Sign up to see every warm intro you have to Remedium
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Remedium team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Remedium Bio is a biotech company developing gene therapy and biologic treatments for osteoarthritis and other rheumatology and metabolic conditions, drawing on research into cartilage regeneration and the FGF18 protein. Its work targets diseases such as osteoarthritis, arthritis, and diabetes-related metabolic conditions.
Founders & leadership
Investors · 5
How we know: Lifespan Vision Ventures's portfolio page · pulse2.com · Not right? Tell us
How we know: Ulu Ventures's portfolio page · Not right? Tell us
How we know: pulse2.com · funding news · Not right? Tell us
Also in the syndicate · 2
Funding
SEC filings, press & company announcements$15.9M disclosed across 3 of 5 rounds · 2021–2026
- $10MSeries AAug 2026 · 5 sources
Lifespan Vision Ventures (lead), Eli Lilly, Eli Lilly and Company, HKX Capital
Source ↗ - Undisclosed amountExpanded Seed FundingAug 2022Source ↗
▶$1.5MraisedMay 2026 · 1 investors · BiotechnologyRule 506(b)
- Alexei GoraltchoukExecutive Officer, Director
- Frank LuppinoExecutive Officer, Director
- Harry RobbDirector
- Richard HagueDirector
- Offering amount
- $10M
- Amount sold
- $1.5M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.4MraisedAug 2024 · 26 investors · BiotechnologyRule 506(b)
- Luppino FrancescoExecutive Officer, Director
- Offering amount
- $7.3M
- Amount sold
- $4.4M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Remedium.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase I | 2023 | $275K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Remedium raises $10m for adjustable gene therapylongevity.technology · Aug 2026
Lifespan Vision Ventures Leads Remedium Bio's Series A Financing - BioSpacebiospace.com · Aug 2026Frequently asked questions
- What does Remedium do?
- Remedium Bio is a biotech company developing gene therapy and biologic treatments for osteoarthritis and other rheumatology and metabolic conditions, drawing on research into cartilage regeneration and the FGF18 protein. Its work targets diseases such as osteoarthritis, arthritis, and diabetes-related metabolic conditions.
- Who are Remedium's investors?
- Remedium's investors include Lifespan Vision Ventures, Ulu Ventures, HKX Capital.
- How much funding has Remedium raised?
- Remedium has disclosed $15.9M raised across 3 of its 5 known rounds.
- Where is Remedium headquartered?
- Remedium is headquartered in Boston, US.